Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - DNIB UNWIND, INC. | d277340d8k.htm |
Exhibit 99.1
UNITED STATES BANKRUPTCY COURT
DISTRICT OF DELAWARE
| In re Bind Therapeutics, Inc. | Case No. 16-11084 (BLS) | |
| Reporting Period: Sep 1 - 30, 2016 |
MONTHLY OPERATING REPORT
File with Court and submit copy to United States Trustee within 20 days after end of month
Submit copy of report to any official committee appointed in the case,
| REQUIRED DOCUMENTS |
Form No. |
Document Attached |
Explanation Attached |
Affidavit/ Supplement Attached | ||||
| Schedule of Cash Receipts and Disbursements |
MOR-1 | Yes | ||||||
| Bank Reconciliation (or copies of debtor’s bank reconciliations) |
MOR-1a | Yes | ||||||
| Schedule of Professional Fees Paid |
MOR-1b | Yes | ||||||
| Copies of bank statements |
||||||||
| Cash disbursements journals |
||||||||
| Statement of Operations |
MOR-2 | Yes | ||||||
| Balance Sheet |
MOR-3 | Yes | ||||||
| Status of Post-petition Taxes |
MOR-4 | |||||||
| Copies of IRS Form 6123 or payment receipt |
||||||||
| Copies of tax returns filed during reporting period |
||||||||
| Summary of Unpaid Post-petition Debts |
MOR-4 | Yes | ||||||
| Listing of aged accounts payable |
MOR-4 | Yes | ||||||
| Accounts Receivable Reconciliation and Aging |
MOR-5 | Yes | ||||||
| Debtor Questionnaire |
MOR-5 | Yes |
I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.
| /s/ Peter Thomson |
10/27/16 | |||
| Signature of Debtor | Date | |||
| /s/ Peter Thomson |
10/27/16 | |||
| Signature of Joint Debtor | Date | |||
| /s/ Geoffrey L. Berman |
10/27/16 | |||
| Signature of Authorized Individual* | Date | |||
| /s/ Geoffrey L. Berman |
CHIEF RESTRUCTURING OFFICER | |||
| Printed Name of Authorized Individual | Title of Authorized Individual | |||
| * | Authorized individual must be an officer, director or shareholder if debtor is a corporation; a partner if debtor is a partnership; a manager or member if debtor is a limited liability company. |
| In re Bind Therapeutics, Inc. | Case No. 16-11084 (BLS) | |
| Debtor | Reporting Period: Sep 1-30, 2016 |
SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS
Amounts reported should be per the debtor’s books, not the bank statement. The beginning cash should be the ending cash from the prior month or, if this is the first report, the amount should be the balance on the date the petition was filled. The amounts reported in the “CURRENT MONTH - ACTUAL” column must equal the sum of the four bank account columns. The amounts reported in the “PROJECTED” columns should be taken from the SMALL BUSINESS INITIAL REPORT (FORM IR-1). Attach copies of the bank statements and the cash disbursements journal. The total disbursements listed in the disbursements journal must equal the total disbursements reported on this page. A bank reconciliation must be attached for each account. [See MOR-1 (CONT)]
| BANK ACCOUNTS | CURRENT MONTH | CUMULATIVE FILING TO DATE | ||||||||||||||||||||||||||||
| OPER. | PAYROLL | TAX | OTHER | ACTUAL | PROJECTED | ACTUAL | PROJECTED | |||||||||||||||||||||||
| CASH BEGINNING OF MONTH |
24,221,333.66 | 24,221,333.66 | ||||||||||||||||||||||||||||
| RECEIPTS | ||||||||||||||||||||||||||||||
| CASH SALES |
||||||||||||||||||||||||||||||
| ACCOUNTS RECEIVABLE |
2,906,803.18 | 2,906,803.18 | ||||||||||||||||||||||||||||
| LOANS AND ADVANCES |
||||||||||||||||||||||||||||||
| SALE OF ASSETS |
||||||||||||||||||||||||||||||
| OTHER (INVESTMENT INCOME) |
863.37 | 863.37 | ||||||||||||||||||||||||||||
| TRANSFERS (FROM DIP ACCTS) |
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||
| TOTAL RECEIPTS |
2,907,666.55 | 2,907,666.55 | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||
| DISBURSEMENTS | ||||||||||||||||||||||||||||||
| NET PAYROLL |
||||||||||||||||||||||||||||||
| PAYROLL TAXES |
||||||||||||||||||||||||||||||
| SALES, USE & OTHER TAXES |
||||||||||||||||||||||||||||||
| INVENTORY PURCHASES |
||||||||||||||||||||||||||||||
| SECURED RENTAL/LEASES |
332,078.05 | 332,078.05 | ||||||||||||||||||||||||||||
| INSURANCE |
39,481.60 | 39,481.60 | ||||||||||||||||||||||||||||
| ADMINISTRATIVE |
545,215.73 | 545,125.73 | ||||||||||||||||||||||||||||
| SELLING |
||||||||||||||||||||||||||||||
| OTHER (RESEARCH AND DEV.) |
342,534.17 | 342,534.17 | ||||||||||||||||||||||||||||
| OTHER (REPAY HERCULES DEBT) |
||||||||||||||||||||||||||||||
| OWNER DRAW* |
||||||||||||||||||||||||||||||
| TRANSFERS (TO DIP ACCTS) |
||||||||||||||||||||||||||||||
| PROFESSIONAL FEES |
644,761.70 | 644,761.70 | ||||||||||||||||||||||||||||
| U.S. TRUSTEE QUARTERLY FEES |
||||||||||||||||||||||||||||||
| COURT COSTS |
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||
| TOTAL DISBURSEMENTS |
1,904,071.25 | 1,904,071.25 | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||
| NET CASH FLOW |
1,003,595.30 | 1,003,595.30 | ||||||||||||||||||||||||||||
| (RECEIPTS LESS DISBURSEMENTS) |
||||||||||||||||||||||||||||||
| CASH - END OF MONTH |
25,224,928.96 | 25,224,928.96 | ||||||||||||||||||||||||||||
| * | COMPENSATION TO SOLE PROPRIETORS FOR SERVICES RENDERED TO BANKRUPTCY ESTATE |
THE FOLLOWING SECTION MUST BE COMPLETED
| DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES (FROM CURRENT MONTH ACTUAL COLUMN) |
| |||
| TOTAL DISBURSEMENTS |
$ | 1,904,071.25 | ||
|
|
|
|||
| LESS: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS |
$ | |||
| PLUS: ESTATE DISBURSEMENTS MADE BY OUTSIDE SOURCES (i.e. from escrow accounts) |
$ | |||
|
|
|
|||
| TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES |
$ | 1,904,071.25 | ||
|
|
|
|||
BIND Therapeutics et al.
MOR 1a - Schedule of Disbursements By Legal Entity
Reporting Period: September 1-30, 2016
| Case No. |
Entity |
Sep 1-30, 2016 | ||||
| 16-11084 | BIND Therapeutics, Inc. | (259,474.08 | ) | |||
| 16-11084 | DNIB Unwind Inc. | (1,644,527.09 | ) | |||
| 16-11085 | BIND Biosciences Security Corp. | (70.08 | ) | |||
|
|
|
|||||
| Total | (1,904,071.25 | ) | ||||
|
|
|
|||||
BIND Therapeutics et al.
MOR 1a - Bank Reconciliation
Reporting Period: September 1-30, 2016
| Case No. |
Entity |
9/30/16 Book |
(+/-) Outstanding Checks |
(+/-) Outstanding Wire |
(+/-) Outstanding Other |
9/30/16 Bank |
Bank |
Description | ||||||||
| 16-11084 |
BIND Therapeutics, Inc. | 104,723.29 | 47,777.21 | — | — | 152,500.50 | Comerica | Operating Account | ||||||||
| 16-11084 |
BIND Therapeutics, Inc. | 559,805.09 | — | — | — | 559,805.09 | Comerica | Restricted Cash | ||||||||
| 16-11084 |
BIND Therapeutics, Inc. | 483.46 | — | — | — | 483.46 | Comerica | Money Market | ||||||||
| 16-11084 |
BIND Therapeutics, Inc. | — | — | — | — | — | Capital Advisors Group | Investment Account | ||||||||
| 16-11084 |
DNIB Unwind, Inc. | 4,118,544.10 | 188,350.41 | — | — | 4,306,894.51 | Signature | Operating Account | ||||||||
| 16-11084 |
DNIB Unwind, Inc. | 21,001,178.11 | — | — | — | 21,001,178.11 | Signature | Money Market | ||||||||
| 16-11085 |
BIND Biosciences Security Corp. | — | — | — | — | — | Capital Advisors Group | Investment Account | ||||||||
|
|
|
|
|
|
||||||||||||
| TOTAL |
25,784,734.05 | 236,127.62 | — | — | 26,020,861.67 | |||||||||||
|
|
|
|
|
|
| In re Bind Therapeutics, Inc. | Case No. 16-11084 (BLS) | |||||||
| Debtor | Reporting Period: Sep 1-30, 2016 |
SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID
This schedule is to include all retained professional payments from case inception to current month.
| Payee |
Period Covered | Amount Covered |
Payor |
Check | Amount Paid | Year-To-Date | ||||||||||||||||||||||||||
| Number | Date | Fees | Expenses | Fees | Expenses | |||||||||||||||||||||||||||
| Richards, Layton, Finger |
Jun 1- Jul 31, 2016 | DNIB Unwind, Inc. | 1034 | 9/29/16 | $ | 65,989.60 | $ | 4,517.12 | $ | 154,901.20 | $ | 5,063.77 | ||||||||||||||||||||
| Prime Clerk |
Jul 1- Aug 31, 2016 | DNIB Unwind, Inc. | 1032 | 9/29/16 | $ | 66,476.50 | $ | 47,229.21 | $ | 115,166.00 | $ | 91,728.91 | ||||||||||||||||||||
| Latham & Watkins |
Jul 1- 31, 2016 | DNIB Unwind, Inc. | Wire | 9/15/16 | $ | 342,726.40 | $ | 8,517.06 | $ | 1,300,439.00 | $ | 52,260.43 | ||||||||||||||||||||
| Cowen |
Jun 1- Jul 31, 2016 | DNIB Unwind, Inc. | 1010 | 9/15/16 | $ | 96,000.00 | $ | 13,305.81 | $ | 156,000.00 | $ | 13,305.81 | ||||||||||||||||||||
YTD amounts reflect payments made from May through September 2016 (case inception to current month)
FORM MOR-1b
(04/07)
| In re Bind Therapeutics, Inc. | Case No. 16-11084 (BLS) | MOR - 2 | ||
| Reporting Period Sep 1-30, 2016 | Statement of Operations | |||
| YTD (Jun) | YTD (Jul) | YTD (Aug) | YTD (Sep) | |||||||||||||
| Partnership Revenue |
6,355,862.42 | 11,580,738.39 | 11,580,738.39 | 11,580,738.39 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Revenue |
6,355,862.42 | 11,580,738.39 | 11,580,738.39 | 11,580,738.39 | ||||||||||||
| R&D |
||||||||||||||||
| Salary & Benefits |
— | — | — | |||||||||||||
| Base Salaries |
4,286,235.76 | 4,564,607.58 | 6,656,877.09 | 6,656,877.09 | ||||||||||||
| Contracted Labor |
224,112.68 | 239,732.18 | 244,863.93 | 244,863.93 | ||||||||||||
| Payroll Taxes |
370,042.28 | 382,450.94 | 382,450.94 | 382,450.94 | ||||||||||||
| Group Health |
358,550.02 | 386,095.92 | 386,095.92 | 386,095.92 | ||||||||||||
| Vacation Expense (accrual adj) |
19,150.00 | 19,150.00 | (200,850.00 | ) | (200,850.00 | ) | ||||||||||
| Bonus Expense |
(449,408.00 | ) | (449,408.00 | ) | (449,408.00 | ) | (449,408.00 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Salary & Benefits |
4,808,682.74 | 5,142,628.62 | 7,020,029.88 | 7,020,029.88 | ||||||||||||
| R&D Consulting |
83,710.63 | 118,014.44 | 146,114.62 | 146,114.62 | ||||||||||||
| Depreciation Expense R&D |
1,295,135.34 | 1,458,766.36 | 1,458,766.36 | 1,458,766.36 | ||||||||||||
| Dues, Subscriptions, & Journals R&D |
210,031.39 | 298,573.47 | 298,573.47 | 298,573.47 | ||||||||||||
| Conferences |
20,022.00 | 20,022.00 | 20,022.00 | 20,022.00 | ||||||||||||
| Travel |
272,782.20 | 239,325.75 | 239,446.34 | 239,446.34 | ||||||||||||
| Meals & Entertainment |
25,631.96 | 25,836.36 | 25,836.36 | 25,836.36 | ||||||||||||
| External R&D |
— | — | — | — | ||||||||||||
| External R&D |
431,171.37 | 479,149.18 | 1,075,643.51 | 1,115,273.78 | ||||||||||||
| Pharmacology |
— | — | — | — | ||||||||||||
| Raw Materials |
647,001.95 | 647,211.95 | 647,811.95 | 648,221.95 | ||||||||||||
| GLP Tox Study |
5,198.49 | 5,198.49 | 5,198.49 | 5,198.49 | ||||||||||||
| GMP Manufacture |
2,750,164.16 | 2,410,598.54 | 1,752,288.64 | 1,764,254.33 | ||||||||||||
| Analytical Activity |
210,918.60 | 194,839.60 | 275,356.66 | 275,356.66 | ||||||||||||
| Clinical Trial |
5,177,551.62 | 5,302,954.84 | 4,226,532.65 | 4,341,422.46 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total External R&D |
9,222,006.19 | 9,039,952.60 | 7,982,831.90 | 8,149,727.67 | ||||||||||||
| Lab Expense |
151,808.81 | 151,808.81 | 152,113.20 | 152,113.20 | ||||||||||||
| Lab Supplies |
1,129,264.96 | 1,154,742.66 | 1,158,952.90 | 1,160,310.84 | ||||||||||||
| Lab Equipment Lease Expense |
13,629.95 | 21,965.58 | 96,553.58 | 100,123.58 | ||||||||||||
| Licenses, Permits, Safety |
4,050.00 | 4,050.00 | 4,050.00 | 4,050.00 | ||||||||||||
| MIT Fees |
124,204.61 | 144,443.28 | 150,688.21 | 150,688.21 | ||||||||||||
| Other In License Fees |
— | — | — | — | ||||||||||||
| Facility Allocation In from G&A |
1,454,036.32 | 1,306,078.45 | 1,306,078.45 | 1,306,078.45 | ||||||||||||
| R&D Stock Compensation-EE |
396,242.00 | 396,242.00 | 396,242.00 | 396,242.00 | ||||||||||||
| R&D Stock Compensation-Consulta |
30,654.00 | 30,654.00 | 30,654.00 | 30,654.00 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Other R&D |
3,303,890.65 | 3,209,984.78 | 3,295,332.34 | 3,300,260.28 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total R&D |
19,241,893.10 | 19,553,104.38 | 20,486,953.27 | 20,658,776.98 | ||||||||||||
| Charges to NIST / RUSSIA Ops NIST Salaries & Benefits |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Other Russian Expenses |
720.72 | 720.72 | 720.72 | 720.72 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total NIST GRANT / Russia Charges |
720.72 | 720.72 | 720.72 | 720.72 | ||||||||||||
| Total R&D |
19,242,613.82 | 19,553,825.10 | 20,487,673.99 | 20,659,497.70 | ||||||||||||
| G&A |
||||||||||||||||
| Salaries & Benefits |
||||||||||||||||
| Salary & Benefits |
12,296.00 | 13,000.01 | 14,728.65 | 14,853.15 | ||||||||||||
| Base Salaries |
1,531,591.19 | 1,809,963.02 | 3,902,232.53 | 3,902,232.53 | ||||||||||||
| Contracted Labor |
183,459.20 | 218,981.70 | 261,436.70 | 261,436.70 | ||||||||||||
| Payroll Taxes |
131,573.74 | 143,982.39 | 187,722.33 | 187,722.33 | ||||||||||||
| Group Health |
89,637.50 | 117,183.40 | 130,869.56 | 166,515.68 | ||||||||||||
| Vacation Expense (accrual adj) |
29,000.00 | 29,000.00 | (44,000.00 | ) | (44,000.00 | ) | ||||||||||
| Bonus Expense |
(416,911.00 | ) | (416,911.00 | ) | (416,911.00 | ) | (416,911.00 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total G&A Salaries & Benefits |
1,560,646.63 | 1,915,199.52 | 4,036,078.77 | 4,071,849.39 | ||||||||||||
| G&A Consulting |
859,840.74 | 829,857.66 | 898,692.85 | 1,436,196.43 | ||||||||||||
| Depreciation Expense G&A |
275,184.90 | 362,404.02 | 362,404.02 | 362,404.02 | ||||||||||||
| Dues, Subscriptions, & Journals R&D |
173,391.23 | 238,639.76 | 244,359.89 | 246,492.81 | ||||||||||||
| Conferences |
7,717.33 | 7,717.33 | 7,717.33 | 7,717.33 | ||||||||||||
| BOD Fees |
198,786.29 | 198,786.29 | 198,786.29 | 198,786.29 | ||||||||||||
| Facility Expense |
— | — | — | — | ||||||||||||
| Rent |
1,254,061.39 | 397,524.01 | 700,314.25 | 1,032,392.30 | ||||||||||||
| Operating Expense |
713,479.63 | 673,479.63 | 673,479.63 | 673,479.63 | ||||||||||||
| Free Rent Adjustment (GAAP) |
(89,127.18 | ) | 58,451.45 | 58,451.45 | 58,451.45 | |||||||||||
| Tenant Improvement - AMORT’N |
(245,879.94 | ) | 196,855.94 | 196,855.94 | 196,855.94 | |||||||||||
| Rent Parking and Transportation |
51,890.00 | 59,700.00 | 59,700.00 | 59,700.00 | ||||||||||||
| RENT - 114 Commonwealth Ave |
— | — | — | — | ||||||||||||
| Repairs & Maintenance |
96,494.50 | 98,991.63 | 110,780.01 | 110,780.01 | ||||||||||||
| Utilities |
— | — | 25,490.38 | 25,490.38 | ||||||||||||
| Moving Expense |
36,627.00 | 36,627.00 | 43,086.00 | 43,086.00 | ||||||||||||
| Facility Alloction Out to R&D |
(1,454,036.32 | ) | (1,306,078.45 | ) | (1,306,078.45 | ) | (1,306,078.45 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Facility Expense |
363,509.08 | 215,551.21 | 562,079.21 | 894,157.26 | ||||||||||||
| Legal |
3,403,427.51 | 3,853,709.51 | 3,751,017.41 | 5,514,496.38 | ||||||||||||
| Legal Patent |
539,145.50 | 589,188.92 | 711,975.90 | 771,530.71 | ||||||||||||
| Insurance |
80,654.48 | 156,735.47 | 1,161,739.15 | 1,161,739.15 | ||||||||||||
| Insurance - D&O |
357,940.02 | 656,223.33 | 656,239.21 | 656,239.21 | ||||||||||||
| Bank Service Charge |
9,741.90 | 9,741.97 | 9,742.04 | 9,742.04 | ||||||||||||
| Audit and Valuation Fees |
295,450.00 | 200,450.00 | 190,450.00 | 190,450.00 | ||||||||||||
| Office Expense & Supplies |
— | — | — | — | ||||||||||||
| Office Expense & Supplies |
51,699.98 | 57,018.86 | 58,912.77 | 59,758.17 | ||||||||||||
| Kitchen Supplies |
— | — | — | — | ||||||||||||
| Computer Supplies |
18,174.70 | 18,174.70 | 18,174.70 | 18,174.70 | ||||||||||||
| Office Equipment Lease |
6,649.20 | 8,011.83 | 8,011.83 | 8,011.83 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Office Expense & Supplies |
76,523.88 | 83,205.39 | 85,099.30 | 85,944.70 | ||||||||||||
| P/R, Marketing & Website |
— | — | — | |||||||||||||
| Recruiting |
||||||||||||||||
| Recruiting |
1,207.00 | 1,207.00 | 1,207.00 | 1,207.00 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Recruiting |
1,207.00 | 1,207.00 | 1,207.00 | 1,207.00 | ||||||||||||
| Postage |
36,005.35 | 37,657.55 | 51,322.47 | 64,671.74 | ||||||||||||
| Printing & Stationery |
66,819.93 | 73,252.90 | 75,546.90 | 76,676.90 | ||||||||||||
| State & Local Tax |
137,414.49 | 138,617.95 | 159,857.95 | (199,582.05 | ) | |||||||||||
| Telephone & Internet |
30,739.01 | 32,636.47 | 33,441.07 | 33,441.07 | ||||||||||||
| Travel |
— | — | — | — | ||||||||||||
| Travel |
66,348.85 | 57,339.12 | 60,031.78 | 60,432.51 | ||||||||||||
| Miscellaneous G&A Expense |
— | — | — | — | ||||||||||||
| Meals & Entertainment |
40,071.58 | 57,750.46 | 60,499.14 | 61,082.47 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Travel |
106,420.43 | 115,089.58 | 120,530.92 | 121,514.98 | ||||||||||||
| Training |
6,494.82 | 6,494.82 | 6,494.82 | 6,494.82 | ||||||||||||
| Unallowed Expenses |
— | — | — | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| G&A Stock Compensation-EE |
332,580.00 | 332,580.00 | 332,580.00 | 332,580.00 | ||||||||||||
| G&A Stock Compensation-Consulta |
241,521.00 | 241,521.00 | 241,521.00 | 241,521.00 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total G&A |
9,161,161.52 | 10,296,467.65 | 13,898,883.50 | 16,286,271.18 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Expenses |
28,403,775.34 | 29,850,292.75 | 34,386,557.49 | 36,945,768.88 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net Ordinary Income |
(22,047,912.92 | ) | (18,269,554.36 | ) | (22,805,819.10 | ) | (25,365,030.49 | ) | ||||||||
| Other Income |
||||||||||||||||
| Interest Income |
28,514.98 | 28,586.39 | 28,978.62 | 29,910.62 | ||||||||||||
| Other Income |
(205,364.65 | ) | (205,364.65 | ) | 32,088,971.91 | 32,088,971.91 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Other Income |
(176,849.67 | ) | (176,778.26 | ) | 32,117,950.53 | 32,118,882.53 | ||||||||||
| Other Expense |
||||||||||||||||
| Interest Expenses |
1,168,494.74 | 1,229,951.52 | 1,229,951.52 | 1,229,951.52 | ||||||||||||
| Interest Expense - Warrants |
(2,612,224.25 | ) | (2,612,224.25 | ) | (2,612,224.25 | ) | (2,757,936.72 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Other Expense |
(1,443,729.51 | ) | (1,382,272.73 | ) | (1,382,272.73 | ) | (1,527,985.20 | ) | ||||||||
| Net Other Income (Expense) |
1,266,879.84 | 1,205,494.47 | 33,500,223.26 | 33,646,867.73 | ||||||||||||
| NET INCOME (LOSS) |
(20,781,033.08 | ) | (17,064,059.89 | ) | 10,694,404.16 | 8,281,837.24 | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| In re Bind Therapeutics, Inc. | Case No. 16-11084 (BLS) | |||
| Reporting Period: September 30, 2016 |
Balance Sheet
| May | June | July | August | September | ||||||||||||||||||
| ASSETS |
||||||||||||||||||||||
| Current Assets |
||||||||||||||||||||||
| Checking/Savings |
||||||||||||||||||||||
| Cash |
1000 | 70.08 | 1,251.93 | 1,252.15 | 1,252.39 | 70.08 | ||||||||||||||||
| Cash-Operating |
1002 | 8,583,197.23 | 6,512,484.89 | 4,340,214.68 | 363,011.75 | 104,723.29 | ||||||||||||||||
| Cash-MM |
1003 | 477.65 | 477.67 | 477.69 | 483.44 | 483.46 | ||||||||||||||||
| Cash DNIB |
856,268.01 | 4,118,544.10 | ||||||||||||||||||||
| Cash MM DNIB |
23,000,315.07 | 21,001,178.11 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Cash and cash equivalents |
8,583,744.96 | 6,514,214.49 | 4,341,944.52 | 24,221,330.66 | 25,224,999.04 | |||||||||||||||||
| Accounts Receivable |
||||||||||||||||||||||
| Accounts Receivables |
1100 | 831,757.28 | 4,095,902.99 | 4,612,438.36 | 4,179,861.86 | 1,258,497.37 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Account Receivable |
831,757.28 | 4,095,902.99 | 4,612,438.36 | 4,179,861.86 | 1,258,497.37 | |||||||||||||||||
| Other Current Assets |
||||||||||||||||||||||
| Prepaid Expense |
1200 | 1,933,509.78 | 1,942,597.64 | 1,091,874.63 | 2,147,700.73 | — | ||||||||||||||||
| Prepaid Clinical |
1202 | 620,610.68 | 718,910.71 | 1,500,000.00 | — | — | ||||||||||||||||
| Other Receivables |
1205 | 1,181.94 | 0.21 | 0.21 | 0.21 | 0.01 | ||||||||||||||||
| Other Current Assets |
1210 | 95,496.68 | — | — | — | — | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Other Current Assets |
2,650,799.08 | 2,661,508.56 | 2,591,874.84 | 2,147,700.94 | 0.01 | |||||||||||||||||
| Short-term Investments |
1220 | — | — | — | — | — | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Current Assets |
12,066,301.32 | 13,271,626.04 | 11,546,257.72 | 30,548,893.46 | 26,483,496.42 | |||||||||||||||||
| Fixed Assets |
||||||||||||||||||||||
| Lab Equipment-Capital Lease |
1325 | 74,553.96 | 74,553.96 | 74,553.96 | — | — | ||||||||||||||||
| Tenant LeaseHold Improvements |
(1360 TO 1361) | 2,383,033.30 | 2,383,033.30 | 2,383,033.30 | — | — | ||||||||||||||||
| Computer Equipment |
1300 | 172,636.59 | 172,636.59 | 172,636.59 | — | — | ||||||||||||||||
| Furniture & Fixtures |
1310 | 92,107.97 | 92,107.97 | 92,107.97 | — | — | ||||||||||||||||
| Lab Equipment |
1320 | 11,625,033.30 | 11,625,033.30 | 11,625,033.30 | — | — | ||||||||||||||||
| Leasehold Improvements |
1350 | 2,319,570.32 | 2,319,570.32 | 2,319,570.32 | — | — | ||||||||||||||||
| Assets Not Yet in Service |
1385 | 0.40 | 0.40 | 0.40 | — | — | ||||||||||||||||
| Accumulated Depreciation |
1390 | (8,042,159.53 | ) | (8,296,706.95 | ) | (8,547,557.09 | ) | — | — | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Fixed Assets |
8,624,776.31 | 8,370,228.89 | 8,119,378.75 | — | — | |||||||||||||||||
| Other Assets |
||||||||||||||||||||||
| Investments-Securities Corp. |
1600 | (46,060.51 | ) | (46,060.51 | ) | (46,060.51 | ) | (46,060.51 | ) | (46,130.59 | ) | |||||||||||
| Investment in Sub - BIND (RUS) |
1610 | 11,069,998.00 | 11,069,998.00 | 11,069,998.00 | 11,069,998.00 | 11,069,998.00 | ||||||||||||||||
| Restricted Cash |
1700 | 559,525.27 | 559,594.06 | 559,665.16 | 559,736.26 | 559,805.09 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Other Assets |
11,583,462.76 | 11,583,531.55 | 11,583,602.65 | 11,583,673.75 | 11,583,672.50 | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| TOTAL ASSETS |
32,274,540.39 | 33,225,386.48 | 31,249,239.12 | 42,132,567.21 | 38,067,168.92 | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| LIABILITIES & EQUITY |
||||||||||||||||||||||
| Current Liabilities |
||||||||||||||||||||||
| Accounts Payable |
||||||||||||||||||||||
| Accounts Payable |
2000 | 6,116,563.28 | 6,518,247.15 | 7,443,755.65 | 2,439,887.50 | 2,463,254.60 | ||||||||||||||||
| BIND Credit Cards |
2010 | 16,408.37 | 16,408.37 | 16,408.37 | 16,408.37 | 16,408.37 | ||||||||||||||||
| Accrued Purchases |
2005 | 260,660.72 | 299,519.45 | 302,314.89 | — | — | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Accounts Payable |
6,393,632.37 | 6,834,174.97 | 7,762,478.91 | 2,456,295.87 | 2,479,662.97 | |||||||||||||||||
| Other Current Liabilities |
||||||||||||||||||||||
| Deferred Revenue |
2150 | 2,854,982.79 | 3,166,921.28 | — | — | — | ||||||||||||||||
| Deferred Rent-ST |
2220 | 647,843.92 | 590,314.50 | — | — | — | ||||||||||||||||
| VC Loan - St |
2260 | 8,151,323.54 | 8,339,466.91 | 7,859,589.39 | 5,712.47 | — | ||||||||||||||||
| FSA Withholding |
2015 | 14,876.76 | 12,919.81 | 5,027.94 | — | — | ||||||||||||||||
| Acrued Expense |
2100 | 1,565,750.01 | 1,201,750.01 | 915,750.01 | — | — | ||||||||||||||||
| Acrued Clinical |
2105 | 958,999.65 | 1,360,299.68 | 1,360,299.68 | — | — | ||||||||||||||||
| Accrued Manufacturing |
2107 | 1,643,000.00 | 1,059,000.00 | 600,000.00 | — | — | ||||||||||||||||
| Accrued Bonus |
2109 | — | — | — | — | — | ||||||||||||||||
| Accrued Vacation |
2111 | 311,000.00 | 293,000.00 | 293,000.00 | — | — | ||||||||||||||||
| Accrued G&A Consulting |
2113 | 37,666.00 | 15,000.00 | 20,000.00 | 20,000.00 | — | ||||||||||||||||
| Accrued Taxes |
2117 | 397,300.00 | 420,200.00 | 420,200.00 | 392,200.00 | — | ||||||||||||||||
| 401K Withheld |
2110 | — | — | — | — | — | ||||||||||||||||
| Accrued Legal |
2119 | 1,577,000.00 | 1,599,500,00 | 1,599,500.00 | 1,118,286.00 | — | ||||||||||||||||
| Accrued Audit |
2121 | 134,167.00 | 170,000.00 | 75,000.00 | — | — | ||||||||||||||||
| Payroll Liabilities |
2200 | 0.02 | — | — | — | — | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Other Current Liabilities |
18,293,909.69 | 18,228,372.19 | 13,148,367.02 | 1,536,198.47 | — | |||||||||||||||||
| Total Current Liabilities |
24,687,542.06 | 25,062,547.16 | 20,910,845.93 | 3,992,494.34 | 2,479,662.97 | |||||||||||||||||
| Long Term Liabilities |
||||||||||||||||||||||
| Warrant Liability |
2245 | 1,795,000.00 | 140,000.00 | 140,000.00 | 140,000.00 | — | ||||||||||||||||
| Deferred Rent-LT |
2500 | — | — | — | — | — | ||||||||||||||||
| Deferred Revenue-LT |
2530 | 2,251,924.26 | 1,541,419.32 | — | — | — | ||||||||||||||||
| VC Loan |
2600 | — | — | — | — | — | ||||||||||||||||
| VC Loan back end fee amort |
2610 | — | — | — | — | — | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Long Term Liabilities |
4,046,924.26 | 1,681,419.32 | 140,000.00 | 140,000.00 | — | |||||||||||||||||
| Total Liabilities |
28,734,466.32 | 26,743,966.48 | 21,050,845.93 | 4,132,494.34 | 2,479,662.97 | |||||||||||||||||
| Equity |
||||||||||||||||||||||
| Opening Balance Equity |
3000 | (54,910.87 | ) | (54,910.87 | ) | (54,910.87 | ) | (54,910.87 | ) | (54,910,87 | ) | |||||||||||
| Common Stock |
3100 | 2,081.47 | 2,081.47 | 2,081.47 | 2,091.24 | 2,091.24 | ||||||||||||||||
| Paid in Capital |
3200 | 194,898,702.05 | 195,331,534.05 | 195,331,534.05 | 195,374,739.91 | 195,374,739.91 | ||||||||||||||||
| Unrealized Gains/Loss on Investments |
3210 | — | — | — | — | — | ||||||||||||||||
| Retained Earnings |
(3900 TO 3901) | (168,016,251.57 | ) | (168,016,251.57 | ) | (168,016,251.57 | ) | (168,016,251.57 | ) | (168,016,251.57 | ) | |||||||||||
| Net Income |
(4000 TO 9900) |
(23,289,547.01 | ) | (20,781,033.08 | ) | (17,064,059.89 | ) | 10,694,404.16 | 8,281,837.24 | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Equity |
3,540,074.07 | 6,481,420.00 | 10,198,393.19 | 38,000,072.87 | 35,587,505.95 | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| TOTAL LIABILITIES & EQUITY |
32,274,540.39 | 33,225,386.48 | 31,249,239.12 | 42,132,567.21 | 38,067,168.92 | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| In re BIND Therapeutics, Inc. | Case No. 16-11084 (BLS) | |||||||
| Debtor | Reporting Period: Sept 1-30, 2016 |
STATUS OF POSTPETITION TAXES
The beginning tax liability should be the ending liability from the prior month or, if this is the first report, the amount should be zero. Attach photocopies of IRS Form 6123 or payment receipt to verify payment or deposit of federal payroll taxes.
Attach photocopies of any tax returns filed during the reporting period.
| Federal |
Beginning Tax Liability | Amount Withheld or Accrued | Amount Paid | Date Paid | Check No. or EFT |
Ending Tax Liability | ||||||||||||||||||
| Withholding |
— | — | ||||||||||||||||||||||
| FICA-Employee |
— | — | ||||||||||||||||||||||
| FICA-Employer |
— | — | ||||||||||||||||||||||
| Unemployment |
— | — | ||||||||||||||||||||||
| Income |
— | — | ||||||||||||||||||||||
| Other: Medicare surtax |
— | — | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Federal Taxes |
— | — | — | — | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| State and Local |
||||||||||||||||||||||||
| Withholding |
— | — | ||||||||||||||||||||||
| Sales |
— | — | — | |||||||||||||||||||||
| Excise |
— | |||||||||||||||||||||||
| Unemployment |
— | — | — | |||||||||||||||||||||
| Real Property |
— | |||||||||||||||||||||||
| Personal Property |
142,200.00 | (142,200.00 | ) | — | — | |||||||||||||||||||
| Other: DE Franchise Tax |
— | — | ||||||||||||||||||||||
| Other: BIND-RUS |
250,000.00 | (250,000.00 | ) | — | — | |||||||||||||||||||
| Other: E&Y |
— | — | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total State and Local |
392,200.00 | (392,200.00 | ) | — | — | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Taxes |
392,200.00 | (392,200.00 | ) | — | — | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
SUMMARY OF UNPAID POSTPETITION DEBTS
Attach aged listing of accounts payable.
| Number of Days Past Due | ||||||||||||||||||||||||
| Current | 0-30 | 31-60 | 61-90 | >90 | Total | |||||||||||||||||||
| Accounts Payable |
39,240 | 78,398 | 60,123 | 78,673 | — | 256,434 | ||||||||||||||||||
| Wages Payable |
— | |||||||||||||||||||||||
| Taxes Payable |
— | |||||||||||||||||||||||
| Rent/Leases-Building |
— | |||||||||||||||||||||||
| Rent/Leases-Equipment |
— | |||||||||||||||||||||||
| Secured debt |
— | |||||||||||||||||||||||
| Professional fees |
— | 85,682 | 50,161 | 722 | 157 | 136,723 | ||||||||||||||||||
| Amounts due to insiders |
— | |||||||||||||||||||||||
| Other: Biology/Chemistry |
— | |||||||||||||||||||||||
| Other: Mfg |
— | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total Postpetition debts: |
39,240 | 164,079 | 110,284 | 79,396 | 157 | 393,156 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Explain how and when the Debtor intends to pay any past-due postpetition debts.
Payments for post-petition debts will be paid in the normal course of business; Payments to ordinary course professionals will be paid in compliance with the Court’s order approving the retention of ordinary course professionals (Docket No. 194), and payments to retained professionals will be paid in compliance with the order establishing procedures for interim compensation and reimbursement of expenses of professionals (Docket No. 152).. * “Insider” is defined in 11 U.S.C. Section 101(31).
Form MOR-4 (4/07)
| In re BIND THERAPEUTICS, INC. | Case No. 16-11084 (BLS) | |||
| Debtor | Reporting Period: September 30, 2016 |
ACCOUNTS RECEIVABLE RECONCILIATION AND AGING
| Accounts Receivable Reconciliation |
Amount | |||||||
| Total Accounts Receivable at the beginning of the reporting period |
$ | 4,179,861,86 | ||||||
| + Amounts billed during the period |
— | |||||||
| - Amounts collected during the period |
$ | 2,921,364.49 | ||||||
|
|
|
|
|
|||||
| Total Accounts Receivable at the end of the reporting period |
$ | 1,258,497.37 | ||||||
|
|
|
|
|
|||||
| Accounts Receivable Aging |
Amount | |||||||
| 0 - 30 days old |
— | |||||||
| 31 - 60 days old |
$ | — | ||||||
| 61 - 90 days old |
$ | 421,680.34 | ||||||
| 91+ days old |
$ | 836,817.03 | ||||||
|
|
|
|
|
|||||
| Total Accounts Receivable |
$ | 1,258,497.37 | ||||||
|
|
|
|
|
|||||
| Amount considered uncollectible (Bad Debt) |
— | |||||||
| Accounts Receivable (Net) |
$ | 1,258,497.37 | ||||||
DEBTOR QUESTIONNAIRE
| Must be completed each month |
Yes |
No | ||||
| 1. | Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below. | X | ||||
| 2. | Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below. | X | ||||
| 3. | Have all postpetition tax returns been timely filed? If no, provide an explanation below. | X | ||||
| 4. | Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below. | X | ||||
| 5. | Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3. | X | ||||
NOTES:
| • | ITEM 3: CALANDAR YE 2015 INCOME TAX RETURNS: POST-EFFECTIVE DATE DEBTORS HAVE ENGAGED AN ACCOUNTANT TO PREPARE THE TAX RETURNS AND THE DEBTORS EXPECT TO BE ABLE TO FILE SUCH RETURNS BY DECEMBER 31, 2016 |
Form MOR-5 (4/07)